相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。FTY720 (fingolimod) is a neuroprotective and disease-modifying agent in cellular and mouse models of Huntington disease
Alba Di Pardo et al.
HUMAN MOLECULAR GENETICS (2014)
The dopamine stabilizers ACR16 and (-)-OSU6162 display nanomolar affinities at the sigma-1 receptor
K. Sahlholm et al.
MOLECULAR PSYCHIATRY (2013)
Pharmacological treatment of chorea in Huntington's disease-good clinical practice versus evidence-based guideline
Ralf Reilmann
MOVEMENT DISORDERS (2013)
A Randomized, Double-Blind, Placebo-Controlled Trial of Pridopidine in Huntington's Disease
Karl Kieburtz et al.
MOVEMENT DISORDERS (2013)
One-year safety and tolerability profile of pridopidine in patients with Huntington disease
Ferdinando Squitieri et al.
NEUROLOGY (2013)
CHANGES IN BRAINSTEM SEROTONERGIC AND DOPAMINERGIC CELL POPULATIONS IN EXPERIMENTAL AND CLINICAL HUNTINGTON'S DISEASE
A. Jahanshahi et al.
NEUROSCIENCE (2013)
Sigma-1 receptor agonist PRE084 is protective against mutant huntingtin-induced cell degeneration: involvement of calpastatin and the NF-κB pathway
A. Hyrskyluoto et al.
CELL DEATH & DISEASE (2013)
The dopaminergic stabilizer, (-)-OSU6162, rescues striatal neurons with normal and expanded polyglutamine chains in huntingtin protein from exposure to free radicals and mitochondrial toxins
C. Ruiz et al.
BRAIN RESEARCH (2012)
Evidence-based guideline: Pharmacologic treatment of chorea in Huntington disease Report of the Guideline Development Subcommittee of the American Academy of Neurology
Melissa J. Armstrong et al.
NEUROLOGY (2012)
Dysregulation of dopamine receptor D2 as a sensitive measure for Huntington disease pathology in model mice
Zachary R. Crook et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Ganglioside GM1 induces phosphorylation of mutant huntingtin and restores normal motor behavior in Huntington disease mice
Alba Di Pardo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders
Teruo Hayashi et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2011)
Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial
Justo Garcia de Yebenes et al.
LANCET NEUROLOGY (2011)
Altered Dopamine and Serotonin Metabolism in Motorically Asymptomatic R6/2 Mice
Fanny Mochel et al.
PLOS ONE (2011)
The Physiology, Signaling, and Pharmacology of Dopamine Receptors
Jean-Martin Beaulieu et al.
PHARMACOLOGICAL REVIEWS (2011)
Efficacy and Safety of the Dopaminergic Stabilizer Pridopidine (ACR16) in Patients With Huntington's Disease
Anders Lundin et al.
CLINICAL NEUROPHARMACOLOGY (2010)
Dopamine and Glutamate in Huntington's Disease: A Balancing Act
Veronique M. Andre et al.
CNS NEUROSCIENCE & THERAPEUTICS (2010)
In vivo pharmacology of the dopaminergic stabilizer pridopidine
Henrik Ponten et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2010)
Impaired Ganglioside Metabolism in Huntington's Disease and Neuroprotective Role of GM1
Vittorio Maglione et al.
JOURNAL OF NEUROSCIENCE (2010)
Poster 19: Validation of the Modified Motor Score (mMS): A Subscale of the Unified Huntington's Disease Rating Scale (UHDRS) Motor Score
S. Waters et al.
Neurotherapeutics (2010)
Is DARPP-32 a potential therapeutic target?
Helton J. Reis et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2007)
Differences in agonist/antagonist properties at human dopamine D2 receptors between aripiprazole, bifeprunox and SDZ 208-912
Yoshihiro Tadori et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2007)
Sigma-1 receptor chaperones at the ER-Mitochondrion interface regulate Ca2+ signaling and cell survival
Teruo Hayashi et al.
CELL (2007)
The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea
Philippe Huot et al.
BRAIN (2007)
Role of brain-derived neurotrophic factor in Huntington's disease
Chiara Zuccato et al.
PROGRESS IN NEUROBIOLOGY (2007)
The dopamine stabilizers (S)-(-)-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonyl-phenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for motor side effects in the rat
Sridhar Natesan et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
The dopaminergic stabiliser ACR16 counteracts the behavioural primitivization induced by the NMDA receptor antagonist MK-801 in mice: implications for cognition
M Nilsson et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2004)
Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders
I Sánchez et al.
NATURE (2003)
Cortical and subcortical lesions impair skilled walking in the ladder rung walking test: a new task to evaluate fore- and hindlimb stepping, placing, and co-ordination
GA Metz et al.
JOURNAL OF NEUROSCIENCE METHODS (2002)
分享论文
